Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer

Zhou, Xing; Li, Yingchun; Jiang, Xiao; Wang, Xiaoxiong; Chen, Shirong; Shen, Taipeng; You, Jie; Hao, Lu; Hong, Lan; Zeng, Li; Cheng, Zhigang

doi:10.3389/fonc.2020.585213

Cited by 22 publications

(48 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Before quantification of PSMA uptake can be used as a biomarker or surrogate endpoint to identify response to treatment, and before we can design sufficiently powered response evaluation studies, a thorough understanding of parameters affecting the quantitative results is required. Uptake of FDG and PSMA differ due to pharmacodynamical differences [ 8 , 9 , 10 ]. Therefore, comparison of uptake measurements from scans with different ligands should be approached with caution.…”

Section: Introductionmentioning

confidence: 99%

Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of 68Ga-PSMA PET/CT Scans

2021

View full text Add to dashboard Cite

Functional imaging with 68Ga prostate-specific membrane antigen (PSMA) and positron emission tomography (PET) can fulfill an important role in treatment selection and adjustment in prostate cancer. This article focusses on quantitative assessment of 68Ga-PSMA-PET. The effect of various parameters on standardized uptake values (SUVs) is explored, and an optimal Bayesian penalized likelihood (BPL) reconstruction is suggested. PET acquisitions of two phantoms consisting of a background compartment and spheres with diameter 4 mm to 37 mm, both filled with solutions of 68Ga in water, were performed with a GE Discovery 710 PET/CT scanner. Recovery coefficients (RCs) in multiple reconstructions with varying noise penalty factors and acquisition times were determined and analyzed. Apparent recovery coefficients of spheres with a diameter smaller than 17 mm were significantly lower than those of spheres with a diameter of 17 mm and bigger (p < 0.001) for a tumor-to-background (T/B) ratio of 10:1 and a scan time of 10 min per bed position. With a T/B ratio of 10:1, the four largest spheres exhibit significantly higher RCs than those with a T/B ratio of 20:1 (p < 0.0001). For spheres with a diameter of 8 mm and less, alignment with the voxel grid potentially affects the RC. Evaluation of PET/CT scans using (semi-)quantitative measures such as SUVs should be performed with great caution, as SUVs are influenced by scanning and reconstruction parameters. Based on the evaluation of multiple reconstructions with different β of phantom scans, an intermediate β (600) is suggested as the optimal value for the reconstruction of clinical 68Ga-PSMA PET/CT scans, considering that both detectability and reproducibility are relevant.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of 68Ga-PSMA PET/CT Scans

2021

View full text Add to dashboard Cite

show abstract

“…The intensity of 18 F-FAPI uptake in organs or benign lesions was quantified in terms of the standardized uptake value (SUV) (SUVmax, and SUVmean). SUVs were acquired by measuring the volume of interest in a 1-or 2-cm spherical region drawn in the parenchyma of organs and benign lesions, according to the size of the organ and 42% threshold isocontour [24,25]. Blood pool SUV was acquired by drawing a 1-cm spherical region in the center of the descending thoracic aorta, excluding the aortic wall.…”

Section: Image Analysis Uptake Values and Study Groupsmentioning

confidence: 99%

Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET/CT imaging

Kou¹,

Jiang²,

Yi³

et al. 2022

Nuclear Medicine Communications

Self Cite

View full text Add to dashboard Cite

Objective To systematically investigate the physiological distribution and benign lesion incidental uptake of Al 18 F-NOTA-FAPI-04 ( 18 F-FAPI) in cancer patients to establish the normal uptake range in relevant organs and lesions.Methods Twenty patients who underwent 18 F-FAPI PET/CT imaging were retrospectively assessed. Organ and benign lesion tracer uptake was quantified based on standardized uptake values (SUVmax and SUVmean). We compared the variation in tracer uptake in certain organs between men and women, analyzed the possible reasons for diffuse uptake in the thyroid, and assessed tracer uptake variations in the uterus in different menstrual cycle phases. Incidental tracer uptake in benign lesions was also assessed. ResultsPhysiological 18 F-FAPI uptake was observed in the urinary tract, biliary tract system, submandibular glands, pancreas, thyroid, uterus, intestine, prostate gland, parotid gland, myocardium, kidney cortex, and muscles, but not the brain, lungs, liver, spleen, colon, and breasts. The SUVmean for each organ was similar for women and men (all P > 0.05). Diffuse tracer uptake in the thyroid was caused by normal thyroid or thyroiditis; there were no statistically significant differences between them

show abstract

“…Therefore, early diagnosis and treatment are important for PCa. Between 27% and 53% of all patients undergoing radical prostatectomy or radiation therapy develop a rising prostate-specific antigen (PSA) level (PSA recurrence) (4). Importantly, patients with PSA recurrence after radical prostatectomy or primary radiation therapy have different risks of subsequent PCa-specific mortality (4).…”

Section: Introductionmentioning

confidence: 99%

Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundWe performed a systematic review and meta-analysis to evaluate the detection rate (DR) of fluoro-prostate-specific membrane antigen (18F-PSMA-1007) PET/CT in patients with different serum prostate-specific antigen (PSA) levels in the setting of primary staging of prostate cancer (PCa) or biochemically recurring PCa.MethodsA comprehensive electronic literature search of the PubMed, Embase, and Cochrane Library databases was conducted in accordance with the PRISMA statement. This study was registered in the PROSPERO database (registration number: CRD42022331595). We calculated the DR of 18F-PSMA-1007 PET/CT in PCa.ResultsThe final analysis included 15 studies that described 1,022 patients and 2,034 lesions with 18F-PSMA-1007 PET/CT in PCa. The DR of 18F-PSMA-1007 PET/CT in patients with PCa in primary staging ranged from 90% to 100%, with a pooled estimate of 94% (95% CI: 92%–96%). The DR of 18F-PSMA-1007 PET/CT in patients with PCa in BCR ranged from 47% to 100%, with a pooled estimate of 86% (95% CI: 76%–95%). The DRs of PSA levels >2.0, 1.1–2.0, 0.51–1.0, and ≤0.5 ng/ml detected by 18F-PSMA-1007 PET/CT in a patient-based analysis were 97% (95% CI: 93%–99%), 95% (95% CI: 88%–99%), 79% (95% CI: 68%–88%), and 68% (95% CI: 58%–78%), respectively.ConclusionThis meta-analysis concluded that 18F-PSMA-1007 PET/CT had a high application value for prostate cancer, including primary tumors and biochemical recurrence. The DR of 18F-PSMA-1007 PET/CT was slightly higher in primary prostate tumors than in biochemical recurrence.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022331595.

show abstract

Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer

Cited by 22 publications

References 29 publications

Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of 68Ga-PSMA PET/CT Scans

Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of 68Ga-PSMA PET/CT Scans

Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET/CT imaging

Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis

Contact Info

Product

Resources

About